Company Overview
CohBar is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics, an emerging class of drugs for the treatment of chronic and age-related diseases. Mitochondria based therapeutics originate from the discovery by CohBar’s founders of a novel group of naturally occurring, mitochondrial peptides encoded in the mitochondrial genome, which regulate metabolism, cell death and other important biological functions, and whose activity declines with age. CohBar’s efforts focus on the development of these peptides into novel therapeutics that offer the potential to address a broad range of large population and orphan diseases. The company and its founders have discovered more than 100 mitochondrial-derived peptides which may be developed into breakthrough treatments for a number of these diseases with enormous unmet medical needs.

CohBar Reports Fourth Quarter 2019 Financial Results and Provides Business Update
Mar 12 2020, 4:02 PM EDT

CohBar to Hold Investor Meetings at the ROTH Virtual Conference
Mar 12 2020, 8:30 AM EDT

CohBar to Announce 2019 Fourth Quarter Financial Results and Provide Business Update on March 12, 2020
Mar 2 2020, 4:30 PM EST

Stock Overview
Symbol    CWBR
Exchange   Nasdaq
Market Cap 54.28m
Last Price $1.2582
52-Week $1.11 - $3.71

Investor Relations
Jordyn Tarazi
Director, Investor Relations
T: (650) 445-4441
jordyn.tarazi@cohbar.com

Management Team
Steven B. Engle, M.S.
Chief Executive Officer, Director
Kenneth C. Cundy, Ph.D.
Chief Scientific Officer
Jeffrey F. Biunno, CPA, MBA
Chief Financial Officer, Secretary and Treasurer
Jon L. Stern, MBA
Chief Operating Officer, Director
Jordyn Tarazi
Director of Investor Relations

CohBar, Inc.
1455 Adams Drive
Suite 2050
Menlo Park, CA 94025

Disclaimer
Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on Form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.